MONTREAL , Aug. 29, 2024 /PRNewswire/ -- Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of correctors for diseases of protein misfolding, including MC4R-deficient genetic obesity, GBA-driven Parkinson's disease and AAT-deficient lung and liver disease, announced today its participation in the following upcoming investor conferences: 22 nd Annual Morgan Stanley Healthcare Conference, September 4-6, 2024 , in New York, NY Clarissa Desjardins , Ph.D.
, CEO of Congruence, will be participating in a fireside chat on Friday, September 6, 2024 at 9:15 am ET Wells Fargo Annual Healthcare Conference, September 4-6, 2024 , in Boston, MA 2024 RBC Capital Markets Biotechnology Private Company Virtual Conference, October 1, 2024 4 th Annual Needham Private Biotech Company Virtual 1x1 Forum, October 8-9, 2024 During these events, Company management will participate in one-on-one meetings with investors. About Congruence Therapeutics Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, RevenirTM, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter.
For more information, please visit www.congruencetx.com .
Company Contact Charles Grubsztajn Chief Operating Officer [email protected] Media Contact Amy Conrad Juniper Point [email protected] 858-366-3243 SOURCE Congruence Therapeutics.
